There have been a number of serious worldwide pandemics due to widespread infections by 46
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was then perfused with solution #2 (0.02% collagenase IV (Sigma-Aldrich) with calcium and 155 magnesium in HBSS) at the same pressure. The liver was then carefully harvested into a Petri 156 dish containing DMEM-15 and 1 × 10 -7 M insulin (Sigma-Aldrich) and minced. This solution 157 was filtered through a 120 µm nylon mesh and centrifuged for 2min at 40 × g at room tempera-158 ture (RT). Cells were washed 2 times with DMEM + insulin. Cells were counted on a hemocy-159 tometer and viability was determined by Trypan blue exclusion. Hepatocytes were plated at a 160 density of 1 × 10 5 cells/ml in DMEM supplemented with 1 × 10 -7 M insulin on a 6-well plate 161 (Corning Inc.). Hepatocytes were incubated for 2 hours and the medium was replaced with serum 162 free DMEM supplemented with 1 × 10 -7 M insulin. Hepatocytes were inoculated with MHV-3 163 (multiplicity of infection (MOI) = 1, 0.1 or 0.01) and incubated for 1h. Cells were then washed 164 with serum free medium + 1 × 10 -7 M insulin and cultured for the indicated time. 165 166 Virus, viral infection and viral titering 167 MHV-3 virus was grown to titers of 10-50 × 10 6 PFU/ml RPMI on confluent 17CL cells. To de-168 termine viral titers, harvested cells or liver tissue, were lysed or homogenized in ice-cold 169 DMEM-10 using a TissueLyser (QIAGEN). MHV-3 titers were assessed on monolayers of L2 170 cells in a standard plaque assay (6). For in vivo studies mice were infected i.p. with 50 PFU of 171 MHV-3 and housed in sterile conditions. Animals were monitored daily and sacrificed at a hu-172 mane end point. 173
174

Histology 175
Tissues were harvested and preserved in 10% buffered formalin. Fixed tissues were paraffin em-176 bedded and cut into 5µm sections by the Department of Pathology at the Hospital for Sick Chil-177 dren (Toronto). Sections were stained with Hematoxylin and Eosin using standard protocols (33) . 178
Sections were scored in a blinded fashion by an experienced liver pathologist (M.J.P.). Sections 179
were assessed for inflammation, parenchymal changes and tissue necrosis. 180 181
Measurement of alanine transaminase (ALT) and (aspartate aminotransferase)AST in the 182
serum 183
Blood was harvested by cardiac puncture and was incubated for 10min at RT. Samples were 184 spun down at 2,000 × g and the serum was collected for analysis. ALT/AST levels were meas-185 ured using the Vitro DT60 II Chemistry System (Ortho Clinical Diagnostics, Neckargemund, 186 Germany). 187 188
Serum protein levels of type I and type II IFN 189
Blood was harvested from mice by cardiac puncture. Serum was incubated at 4°C overnight 190 (O/N). The samples were centrifuged at 2,000 × g for 10min and the serum was removed to a 191 fresh tube. ELISA kits for IFN-α and IFN-β were purchased from PBL Interferon Source (Pis-192 cataway Township, NJ, USA). The ELISA kit for IFN-γ was purchased from BioLegend Inc 193 (San Diego, CA, USA). ELISA tests were performed according to manufacturer 's instructions. 194 195
Real Time PCR 196
Mice were infected with MHV-3 and sacrificed on the indicated day(s). Total RNA was ex-197 tracted from liver tissue using TRIzol reagent (Invitrogen) according to manufacturer's specifica-198 tions. The isolated RNA was treated with DNase (Qiagen) and the quality of the RNA was as-199 sessed by measuring 260/280 on a Nanodrop spectrophotometer. 1µg of RNA was reverse tran-200 scribed using the First Strand cDNA Synthesis Kit (GE Health Care) using random hexamer oli-201 gonucleotides. The reverse transcriptase reaction was run as per manufacturer's specifications. 202
Primers used for Real Time PCR reactions were based on published and primer bank sequences. 203
The following primer sequences were used: mouse IFN-α forward primer 5'-204 Real Time PCR was performed on an ABI PRISM 7900H (Applied Biosystems) with SYBR 217
Green real time PCR master mix (Applied Biosystems) according to manufacturer's specifica-218 tions using the 96-well plate format. Data was analyzed using SDS 2.2 Software (Applied Bio-219 systems) using the standard curve method. Samples were normalized to HPRT and GAPDH. 
PLP2 Inhibition 246
PLP2 inhibitors were generated in house according to Ratia et al (34) . Isolated PEM were incu-247 bated in the presence of MHV-3 (MOI=1) for 1h. Medium was washed away and fresh medium 248 ± 100µM inhibitor 6, 100µM inhibitor 7, 100µM GRL0617 or 100IU/ml IFN-α was added (PBL 249 Interferon Source). Cells were harvested at 9h p.i., run on a 10% SDS PAGE gel and visualized 250 by WB. 251
252
Statistics 253
Statistical analysis was performed using PRISM software version 5 (GraphPad Software Inc). 254
Survival curves were calculated using the Log-rank (Mantel-Cox) test. 255
Data analysis was performed using a 2-way ANOVA followed by a Bonferroni post-hoc test 256 unless otherwise noted. Data is represented as either mean ± SD or mean ± SEM as indicated. 257
Results with a p value below 0.05 were considered significant. 
USP18
+/+ mice. However, at day 7 p.i., the USP18 -/-pathogenesis approached levels comparable 282 to USP18 +/+ mice at day 3 p.i. in all 3 of the measured criteria including histology, serum 283 transaminase levels and viral titers ( Figure 1E ). Therefore, the absence of USP18 confers an 284 early antiviral advantage against MHV-3 infection. However, USP18
-/-mice ultimately suc-285 cumbed to infection. 286
MHV-3 infection does not induce type I IFN in USP18
-/-mice 288
USP18
- Finally, USP18 -/-peritoneal exudative macrophages (PEM) that were infected with MHV-3 did 300 not show increased Type I IFN signalling, as seen by the absence of STAT1 phosphorylation 301 (data not shown). These data imply that the increased antiviral activity against MHV-3 observed 302 in the USP18 -/-mice is not due to increased IFN production or signalling. 303 304
Cellular ISGylation inhibits MHV-3 Replication 305
Since the decrease in MHV-3 replication and mortality following infection of USP18 -/-306 mice is not due to increased IFN or Type I IFN signalling, we asked whether decreased MHV-3 307 replication and mortality was due to increased levels of ISGylation (21). First, we examined 308 whether the decreased proliferation of MHV-3 in USP18 -/-in vivo could be replicated in vitro in 309 16 primary hepatocytes. Hepatocytes isolated from USP18 +/+ and USP18 -/-mice were infected with 310 MHV-3 (multiplicity of infection (MOI)=1) and viral titers were measured up to 48h p.i. (Figure  311 3A). USP18 +/+ hepatocytes reached peak MHV-3 titers, 2.09 × 10 7 ± 1.29 × 10 6 PFU, between 312 12-18h p.i. Viral titers remained elevated until 36h p.i, after which the levels started to decrease, 313 presumably due to cell death. Viral titers increased in USP18 -/-hepatocytes with slower kinetics 314 than USP18 +/+ mice, with nearly a log decrease in MHV-3 titers at almost all time points. How-315 ever, USP18 -/-mice reached peak viral titers at 36h at 1.03 × 10 7 ± 2.31 × 10 5 PFU, more than 316 18h after USP18 +/+ peak titers. These in vitro results support the in vivo finding that MHV-3 viral 317 titers are suppressed in the presence of increased ISGylation. Although the viral titers in USP18 -/-318 hepatocytes are suppressed initially, the virus eventually overwhelms the antiviral response. This 319 is similar to the extended survival seen in USP18 -/-mice, but these mice ultimately succumb to 320 MHV-3 infection. Of note, at early time points following MHV-3 inoculation, namely 1h, 3h and 321 6h, viral titers of USP18 +/+ and USP18 -/-mice do not differ significantly (2-way ANOVA with 322
Bonferroni post-hoc test). This suggests that viral binding and entry into the cell may not be af-323 fected by interferon stimulated gene (ISG)-15 antiviral activity however, further studies are re-324 quired to differentiate the effects of ISGylation on viral binding and entry and viral replication. 325
The amount of ISG15-conjugated proteins is markedly higher in USP18 -/-hepatocytes 326 than USP18 +/+ hepatocytes at all time points following MHV-3 infection ( Figure 3B ). The ex-327 pression of viral nucleocapsid (N) protein is detectable by WB starting at 6h p.i. in USP18 +/+ 328 hepatocytes and continues to accumulate until 18h ( Figure 3B ) when peak N protein expression 329 coincides with peak viral titers ( Figure 3A (Fig 2A-D) . By contrast, MHV-3 infection of USP18 -/-mice resulted in little, 422 if any, IFN production at either the mRNA or protein levels. At first glance this is surprising, 423 since USP18 -/-mice are hypersensitive to IFN, and we expected that any IFN-β produced upon 424 exposure to MHV-3 virus would stimulate IFN-α production in a positive feedback loop (53). 425
Furthermore, the increased ISGylation observed in USP18 -/-cells would be expected to lead to 426 increased IFN production since the direct ISGylation of interferon regulatory transcription fac-427 tor-3 (IRF-3) prolongs the activation of IRF-3 and results in increased expression of IFN-β and 428 other ISGs (41). However, we observed an almost complete absence of type I IFN production in 429 response to MHV-3. While it is tempting to ascribe the lack of IFN production to the increased 430 ISGylation seen in USP18 -/-cells, this is unlikely. Firstly, USP18 was shown to regulate type I 431 IFN induction independent of isopeptidase activity and that ISG15 antiviral activity is independ-432 ent of IFN signalling (22, 43) . Secondly, the observed lack of a type I IFN response may also be 433 due to differences in the immune cell phenotype of USP18 -/-mice. Cong et al described a 434 USP18-dependent but ISGylation-independent difference in dendritic cell maturation (54). Simi-435 larly, we have observed a fundamental difference in the phenotype of USP18 -/-macrophages and 436 kupffer cells, with a shift from the M1 pro-inflammatory phenotype in USP18 +/+ mice to an M2 437 regulatory phenotype in USP18 -/-mice (manuscript in preparation). This result may suggest that 438 22 the fact that MHV-3 does not induce IFN is not specific to the virus but the phenotype of the 439
USP18
-/-macrophages and dendritic cells, both of which are key producers of hepatic IFN (23, 440 53, 55) . Differences in immune cell phenotype and the consequent lack of IFN production in 441
-/-mice raise the possibility of confounding immune effects in our in vivo data. However, 442 the lack of a type I IFN response in the USP18 -/-mice would be expected to promote viral repli-443 cation, but we observed the reverse effect. The lack of IFN signalling thus allows us to attribute 444 our results to ISGylation as opposed to IFN signalling in USP18 -/-mice. 445
The mechanism by which ISGylation exerts an antiviral activity against MHV-3 is un- -/-mice. AST and ALT were measured and represented as log(U/L) ± SD. E) 700
-/-mice show decreased viral titers. Viral titers were measured daily until day 4 and on 701 day 7 only in USP18 -/-mice using a standard plaque assay. Data is represented as the mean 702 log(PFU/g) ± SD. *** p<0.001, ** p<0.01, *p<0.05. 
